Article
Oncology
Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
Summary: This study aims to evaluate the possibility and effectiveness of de-escalation of postoperative radiotherapy for pN1 breast cancer patients after breast-conserving surgery or mastectomy. It will compare different radiotherapy strategies in terms of treatment outcomes and toxicity rates, providing important evidence for individualized radiotherapy strategies for pN1 breast cancer patients.
Article
Medicine, General & Internal
Timothy J. Whelan, Sally Smith, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Eileen Rakovitch, Lynn Chang, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Valerie Theberge, Anna Marie Mulligan, Zuzana Kos, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Pond, James R. Wright, Torsten O. Nielsen, Mark N. Levine
Summary: Among women with T1N0 grade 1 or 2 luminal A breast cancer who had undergone breast-conserving surgery and received endocrine therapy, the incidence of local recurrence at 5 years was low without radiotherapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Sankha S. Basu, Sylwia A. Stopka, Walid M. Abdelmoula, Elizabeth C. Randall, Begona Gimenez-Cassina Lopez, Michael S. Regan, David Calligaris, Fake F. Lu, Isaiah Norton, Melissa A. Mallory, Sandro Santagata, Deborah A. Dillon, Mehra Golshan, Nathalie Y. R. Agar
Summary: This study describes the clinical application of MS to assess breast cancer margins during surgery. Five candidate ions were identified in a limited dataset to distinguish tumors from healthy tissue, but further data is needed to confirm their validity. Lessons learned from this study will help further evaluate and optimize the use of intraoperative MS as a tool for surgical guidance in breast cancer.
Article
Oncology
Arielle S. Radin, Julienne E. Bower, Michael R. Irwin, Arash Asher, Sara A. Hurvitz, Steve W. Cole, Catherine M. Crespi, Patricia A. Ganz
Summary: Contemporary breast cancer surgical procedures vary in terms of tissue removal, anesthesia time, and reconstruction. However, limited data exists on the health-related quality of life (HRQOL) outcomes and biological processes associated with contemporary surgical procedures. Two studies were conducted to examine the differences in post-operative functioning, pain, fatigue, and systemic inflammatory markers among women with early-stage breast cancer. The results indicate that more extensive surgery is associated with poorer postoperative HRQOL and higher concentrations of systemic inflammatory markers compared to less extensive surgery or no surgery.
Article
Endocrinology & Metabolism
Jin Hu, Yanting Zhang, Fang Dong, Jian Shen, Hengyu Chen, Lei Li, Tao Huang
Summary: The study evaluated the effect of HER2 status on metaplastic breast cancer (MBC) patients using propensity-score matching. The findings suggest that HER2-negative patients can benefit from post-mastectomy radiotherapy (PMRT) with better prognosis, while HER2-positive patients do not show significant improvement in prognosis after PMRT.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Marissa K. Srour, Joshua Tseng, Alice Chung, Armando E. Giuliano, Farin Amersi
Summary: A study evaluated national trends in compliance with breast cancer quality metrics using the National Cancer Database. Overall compliance rates for radiation after breast-conserving surgery, radiation after mastectomy, and hormonal therapy have increased to meet CoC standards, while compliance for radiation after mastectomy has regressed. Community programs were found to be the least compliant with meeting the CoC standards.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Hong Bae Jeon, Ji Hyuk Jung, Sang Hee Im, Yong Bae Kim, Jee Suk Chang, Seung Yong Song, Dae Hyun Lew, Tai Suk Roh, Won Jai Lee, Dong Won Lee
Summary: This study aimed to investigate the impact of immediate breast reconstruction on the risk of breast cancer-related lymphedema. The results showed that immediate breast reconstruction can reduce the incidence of lymphedema.
PLASTIC AND RECONSTRUCTIVE SURGERY
(2023)
Article
Oncology
Dario Pasalic, Eric A. Strom, Pamela K. Allen, Tyler D. Williamson, Falk Poenisch, Richard A. Amos, Wendy A. Woodward, Michael C. Stauder, Simona F. Shaitelman, Benjamin D. Smith, George H. Perkins, Welela Tereffe, Karen E. Hoffman
Summary: The study conducted a planned interim analysis of acute and late toxicities as well as cosmetic outcomes after proton accelerated partial breast irradiation for breast cancer. Results show high local control, favorable cosmetic outcomes, and high treatment satisfaction among patients and physicians. The most commonly reported late cosmetic effect was telangiectasis.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Editorial Material
Medicine, General & Internal
Alice Y. Ho, Jennifer R. Bellon
Summary: In this Journal article, the 10-year results of the anticipated PRIME II trial are reported. The results suggest that omitting radiotherapy after breast-conserving surgery has no impact on survival in women aged 65 or older with low-risk breast cancer. These findings address the issue of overtreatment in older women with low-risk breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Trudy C. C. Wu, Susan A. A. McCloskey
Summary: Modern advances in diagnostics, surgery, systemic therapies, and radiotherapy have revolutionized treatment strategies for breast cancer. This review discusses current and evolving treatment paradigms for radiotherapy in breast-conserving therapy and post-mastectomy setting. The article also addresses the investigation of omitting radiotherapy in certain cases, the potential of hypofractionated radiotherapy, and the role of ablative radiotherapy in oligometastatic breast cancer.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Dan-Qiong Wang, Na Zhang, Li-Hua Dong, Ya-Hua Zhong, Hong-Fen Wu, Qiu-Zi Zhong, Jing Jin, Xiao-Rong Hou, Hao Jing, Yu Tang, Chen Hu, Yong-Wen Song, Yue-Ping Liu, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Bo Chen, Yi-Rui Zhai, Wen-Wen Zhang, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
Summary: The objective of this study was to assess the incidence and dose-volume predictors of radiation esophagitis (RE) in breast cancer patients undergoing hypofractionated regional nodal irradiation. The study found that the incidence of grade 2 and 3 RE was 40.9% and 0.3% respectively, with no grade 4 or 5 RE occurring within 6 months after radiation therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Rinat Bernstein-Molho, Yael Laitman, Shira Galper, Galia Jacobson, Ben Boursi, Einav Nili Gal-Yam, Bella Kaufman, Eitan Friedman, Orit Kaidar-Person
Summary: This study found that BRCA1/2 mutation carriers with breast cancer who did not receive postmastectomy radiation therapy had higher rates of ipsilateral breast tumor recurrence. Despite earlier disease stages, their recurrence rates were higher compared to those who received postmastectomy radiation therapy or breast-conserving treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Surgery
R. Kate Pawloski, V. Andrea Barrio, L. Mary Gemignani, Varadan Sevilimedu, Tiana Le, Joseph Dayan, Monica Morrow, B. Audree Tadros
Summary: Immediate reconstruction (IR) in women with T4 breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation therapy is associated with delayed initiation of adjuvant treatment and increased risk of complications, particularly in those with T4d disease. It is advisable to wait at least 18 months after mastectomy before considering reconstruction.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
(2021)
Editorial Material
Oncology
Sarah P. Shubeck, Monica Morrow, Lesly A. Dossett
Summary: Several trials of breast cancer treatment have failed to show a survival benefit for certain surgical therapies that were previously considered routine. The deimplementation of these therapies varies significantly, indicating that effective de-escalation in breast cancer surgery is influenced by factors beyond randomized controlled trials and high-quality evidence, such as stakeholders, social expectations, and environmental contexts.
Article
Oncology
Ivica Ratosa, Gaber Plavc, Nina Pislar, Tina Zagar, Andraz Perhavec, Pierfrancesco Franco
Summary: This study compared survival outcomes in 1360 patients with early-stage breast cancer, showing that patients treated with breast-conserving therapy had lower rates of recurrence and equivalent overall survival compared to those treated with mastectomy alone. The findings emphasize the importance of adjuvant treatments, including radiation therapy, in improving disease-specific outcomes for early-stage breast cancer patients.
Article
Oncology
Nour Abuhadra, Ryan Sun, Jennifer K. Litton, Gaiane M. Rauch, Clinton Yam, Jeffrey T. Chang, Sahil Seth, Roland Bassett, Bora Lim, Alastair M. Thompson, Elizabeth Mittendorf, Beatriz E. Adrada, Senthil Damodaran, Jason White, Elizabeth Ravenberg, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Aysegul A. Sahin, Vicente Valero, William Fraser Symmans, Debu Tripathy, Stacy Moulder, Lei Huo
Summary: In TNBC patients without a complete pathologic response, high baseline stromal tumor-infiltrating lymphocytes (sTILs) did not show a significant association with event-free survival (EFS), suggesting that sTILs may not confer a benefit in EFS in the absence of a pCR. RNA-seq analysis revealed more CD8+ T cells in the high-sTIL group with favorable EFS, indicating lymphocyte type may be an important parameter for de-escalation strategies. Further research is needed to investigate the implications of these findings in the context of immune checkpoint inhibitor therapy.
Article
Oncology
Maitri Kalra, Elizabeth Henry, Kelly McCann, Meghan S. Karuturi, Jean G. Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S. Mougalian, Gregory Durm, Angel Qin, Caitlin Schonewolf, Meghna Trivedi, Avan J. Armaghani, Frederick H. Wilson, Wade T. Iams, Anita A. Turk, Praveen Vikas, Michael Cecchini, Sam Lubner, Priyadarshini Pathak, Kristen Spencer, Vadim S. Koshkin, Matthew K. Labriola, Catherine H. Marshall, Katy E. Beckermann, Marina N. Sharifi, Anthony C. Bejjani, Varsha Hotchandani, Samir Housri, Nadine Housri
Summary: Academics from National Cancer Institute-designated Comprehensive Cancer Centers in the United States share expert knowledge with oncologists across the country through an online Q&A platform, significantly impacting clinical practices, improving patient care, and providing a source of new knowledge and education in the field of oncology.
Article
Oncology
Rashi Kalra, Ching Hui Chen, Junkai Wang, Ahmad Bin Salam, Lacey E. Dobrolecki, Alaina Lewis, Christina Sallas, Clayton C. Yates, Carolina Gutierrez, Balasubramanyam Karanam, Meenakshi Anurag, Bora Lim, Matthew J. Ellis, Shyam M. Kavuri
Summary: This study demonstrates that recurrent HER2 mutations have differential effects on therapy responsiveness, metastasis, and therapeutic sensitivity, and the type of mutation may depend on the histological background of breast cancer.
Article
Oncology
Hillary Stires, Igor Bado, Thelma Brown, Martha Carlson, Isaac S. Chan, Gloria V. Echeverria, Andrew J. Ewald, Bora Lim, Carla Lloyd, Julia Maues, Steffi Oesterreich, Robert N. Riter, Kelly Shanahan, Alana L. Welm, Josh Newby
Summary: Incorporating patient advocates into basic cancer research can enhance research intentionality, effective communication, and direct connections between researchers and those they aim to help. However, many cancer research scientists do not collaborate with patient advocates. Through hosting workshops and discussing findings at an international conference, we identified barriers and provided actionable steps to support researchers in working with patient advocates to improve cancer research and achieve our collective goal.
Article
Statistics & Probability
Juhee Lee, Peter F. Thall, Bora Lim, Pavlos Msaouel
Summary: A Bayesian method for personalized treatment selection is proposed, which takes into account the risk-benefit trade-off. A utility function varying with age is used to quantify the desirability of different outcome combinations, and a Bayesian nonparametric multivariate regression model is fitted to the trial data. The optimal treatment depends on the patient's age, with combination treatment preferable for patients 70 years or younger and single agent treatment preferable for patients older than 70.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS
(2022)
Article
Cell Biology
Yaohua Zhang, Chengcao Sun, Yajuan Li, Juan Qin, Kaushik Amancherla, Ying Jing, Qingsong Hu, Ke Liang, Zhao Zhang, Youqiong Ye, Lisa A. Huang, Tina K. Nguyen, Sergey D. Egranov, Zilong Zhao, Andrew Wu, Yutao Xi, Jun Yao, Mien-Chie Hung, George A. Calin, Jie Cheng, Bora Lim, Lorenz H. Lehmann, Joe-Elie Salem, Douglas B. Johnson, Michael A. Curran, Dihua Yu, Leng Han, Radbod Darabi, Liuqing Yang, Javid J. Moslehi, Chunru Lin
Summary: This study found that tumor-bearing mice treated with immune checkpoint inhibitors (ICIs) for cancer showed cardiovascular toxicities, including myocarditis and arrhythmia. Female mice were more susceptible to myocarditis. The down-regulation of MANF and HSPA5 in the heart tissue was associated with these cardiac effects.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Meenakshi Anurag, Eric J. Jaehnig, Karsten Krug, Jonathan T. Lei, Erik J. Bergstrom, Beom-Jun Kim, Tanmayi D. Vashist, Anh Minh Tran Huynh, Yongchao Dou, Xuxu Gou, Chen Huang, Zhiao Shi, Bo Wen, Viktoriya Korchina, Richard A. Gibbs, Donna M. Muzny, Harshavardhan Doddapaneni, Lacey E. Dobrolecki, Henry Rodriguez, Ana I. Robles, Tara Hiltke, Michael T. Lewis, Julie R. Nangia, Maryam Nemati Shafaee, Shunqiang Li, Ian S. Hagemann, Jeremy Hoog, Bora Lim, C. Kent Osborne, D. R. Mani, Michael A. Gillette, Bing Zhang, Gloria V. Echeverria, George Miles, Mothaffar F. Rimawi, Steven A. Carr, Foluso O. Ademuyiwa, Shankha Satpathy, Matthew J. Ellis
Summary: Microscaled proteogenomics was used to study the molecular basis of differential response to neoadjuvant carboplatin and docetaxel combination chemotherapy for triple-negative breast cancer. The study revealed metabolic pathways and genomic alterations associated with resistance and sensitivity to the treatment. Additionally, the deletion of a gene region was found to be associated with resistance, poor prognosis, and chromosomal instability.
Article
Cell Biology
Gonghong Yan, Augustin Luna, Heping Wang, Behnaz Bozorgui, Xubin Li, Maga Sanchez, Zeynep Dereli, Nermin Kahraman, Goknur Kara, Xiaohua Chen, Caishang Zheng, Daniel McGrail, Nidhi Sahni, Yiling Lu, Ozgun Babur, Murat Cokol, Bora Lim, Bulent Ozpolat, Chris Sander, Gordon B. Mills, Anil Korkut
Summary: This study suggests that targeting MCL1 and BET may have therapeutic potential for the treatment of basal-like breast cancers. BET inhibition induces an adaptive response leading to the evasion of apoptosis in breast cancer cells driven by MCL1 protein. The mechanism involves upregulation of lipid synthesis enzymes, which affects cell motility and membrane fluidity, as well as the activation of HER2/EGFR signaling. MCL1 copy-number alterations are associated with the effectiveness of BET and MCL1 co-targeting.
Article
Biochemistry & Molecular Biology
Mokryun L. Baek, Junegoo Lee, Katherine E. Pendleton, Mariah J. Berner, Emily B. Goff, Lin Tan, Sara A. Martinez, Iqbal Mahmud, Tao Wang, Matthew D. Meyer, Bora Lim, James P. Barrish, Weston Porter, Philip L. Lorenzi, Gloria V. Echeverria
Summary: It was found that mitochondrial oxidative phosphorylation (OXPHOS) was elevated in triple negative breast cancer (TNBC) cells surviving neoadjuvant chemotherapy (NACT). DNA-damaging agents increased mitochondrial fusion and OXPHOS, while taxanes decreased these effects. Inhibiting mitochondrial fusion and fission suppressed regrowth of residual tumor cells. These findings offer potential strategies to overcome mitochondrial adaptations in chemoresistant TNBC.
Article
Multidisciplinary Sciences
Daniel Wang, Caroline E. Porter, Bora Lim, Amanda Rosewell Shaw, Catherine S. Robertson, Mae L. Woods, Ya Xu, Greyson G. W. Biegert, Daisuke Morita, Tao Wang, Bambi J. Grilley, Helen Heslop, Malcolm K. Brenner, Masataka Suzuki
Summary: We have demonstrated the strong antitumor activity of a binary oncolytic/helper-dependent adenovirus (CAdVEC) that lyses tumor cells, expresses IL-12 and PD-L1 blocking antibody. Following successful preclinical studies, we treated four patients with an ultralow dose of CAdVEC, which resulted in significant tumor control and immune repolarization. The combination of CAdVEC with systemic immune checkpoint antibodies induced sustained antitumor responses.
Article
Oncology
Nour Abuhadra, Ryan Sun, Clinton Yam, Gaiane M. Rauch, Qingqing Ding, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz E. Adrada, Senthil Damodaran, Kiran Virani, Jason White, Elizabeth Ravenberg, Jia Sun, Jaihee Choi, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Jennifer K. Litton, Debu Tripathy, Stacy Moulder, Lei Huo
Summary: In this study, clinicopathologic features, including sTILs, Ki-67, PD-L1, and androgen receptor, were evaluated in 408 early-stage TNBC patients. Integrating high Ki-67 (>35%) and high sTILs (≥20%) in a computed response score model predicted a pCR rate of 65%. This model has the potential to refine patient selection for neoadjuvant clinical trials evaluating de-escalation strategies.
Article
Oncology
Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, Phillip Peabody, Heather B. McBride, Franklin D. Alvarez, Megumi Kai, Juhee Song, Yu Shen, Jie S. Willey, Bora Lim, Vicente Valero, Naoto T. Ueno, James M. Reuben
Summary: Circulating tumor cells (CTCs) are valuable indicators for managing metastatic breast cancer (MBC). Enrichment of CTCs based on size and deformability can capture a wider range of tumor cells, providing a complementary approach to tissue biopsy. A longitudinal study using a microcavity array showed that the shift from epithelial CTCs to those with a mesenchymal expression pattern is associated with worse clinical outcomes.
Article
Oncology
Hui Chen, Qingqing Ding, Laila Khazai, Li Zhao, Senthil Damodaran, Jennifer K. Litton, Gaiane M. Rauch, Clinton Yam, Jeffrey T. Chang, Sahil Seth, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz Adrada, Kiran Virani, Jason B. White, Elizabeth Ravenberg, Xingzhi Song, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Mark J. Routbort, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Debu Tripathy, Wei-Lien Wang, Stacy Moulder, Lei Huo
Summary: This study compared the differences in PTEN expression between pre- and post-treatment tumors in patients with triple-negative breast cancer (TNBC). It also explored the possibility of using next-generation sequencing (NGS) as an alternative to immunohistochemistry (IHC) to identify PTEN loss. The results showed that testing different specimens by IHC may generate different PTEN results in a small proportion of TNBC patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Computer Science, Artificial Intelligence
Ehsan Irajizad, Ranran Wu, Jody Vykoukal, Eunice Murage, Rachelle Spencer, Jennifer B. Dennison, Stacy Moulder, Elizabeth Ravenberg, Bora Lim, Jennifer Litton, Debu Tripathym, Vicente Valero, Senthil Damodaran, Gaiane M. Rauch, Beatriz Adrada, Rosalind Candelaria, Jason B. White, Abenaa Brewster, Banu Arun, James P. P. Long, Kim Anh Do, Sam Hanash, Johannes F. Fahrmann
Summary: This study identified a polyamine signature in the blood associated with triple-negative breast cancer (TNBC) development and progression. Elevated levels of acetylated polyamines were found in TNBC patients with moderate to extensive tumor burden following neoadjuvant chemotherapy (NACT). Using deep learning model analysis, a panel of metabolites, including two polyamines and nine additional metabolites, was developed for improved prediction of treatment response. These findings have clinical value in identifying TNBC patients unlikely to respond to NACT and who may benefit from alternative treatments.
FRONTIERS IN ARTIFICIAL INTELLIGENCE
(2022)
Review
Oncology
Evthokia A. Hobbs, Natalie Chen, Alphi Kuriakose, Elizabeth Bonefas, Bora Lim
Summary: Breast cancer is a heterogeneous disease that presents challenges for biomarker-driven research and targeted therapies. Early detection, adaptation to chemotherapy resistance, and personalized treatment can improve outcomes. This review focuses on predictive biomarkers and detection methods for metastatic breast cancer.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)